Zydus Lifesciences Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Zydus Lifesciences de 8.3% y 7.4% por año respectivamente. Se prevé que el BPA crezca en un 9.2% al año. Se espera que la rentabilidad financiera sea de 13.5% en 3 años.

Información clave

8.4%

Tasa de crecimiento de los beneficios

9.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.8%
Tasa de crecimiento de los ingresos	7.5%
Rentabilidad financiera futura	13.5%
Cobertura de analistas	Good
Última actualización	25 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Recent updates

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Mar 18

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Dec 27

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Dec 06

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Aug 23

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Jul 17

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Jul 15

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Jun 24

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Shares Could Be 23% Below Their Intrinsic Value Estimate

Aug 09

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 25

Zydus Lifesciences (NSE:ZYDUSLIFE) Has Announced That Its Dividend Will Be Reduced To ₹2.50

Jul 10

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Jul 07

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 23

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Reducing Its Dividend To ₹2.50

Jun 09

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Reduced To ₹2.50

May 26

Previsiones de crecimiento de beneficios e ingresos

NSEI:ZYDUSLIFE - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	235,466	34,771	25,795	N/A	2
3/31/2026	225,568	38,554	33,466	N/A	25
3/31/2025	210,288	37,344	29,501	N/A	27
3/31/2024	192,760	35,800	28,616	N/A	27
12/31/2023	190,241	29,562	N/A	N/A	N/A
9/30/2023	187,760	28,109	28,078	37,726	N/A
6/30/2023	184,127	25,262	N/A	N/A	N/A
3/31/2023	172,374	19,649	16,579	26,888	N/A
12/31/2022	164,335	20,785	N/A	N/A	N/A
9/30/2022	157,110	19,629	8,934	20,209	N/A
6/30/2022	153,361	21,710	N/A	N/A	N/A
3/31/2022	151,099	22,416	10,146	21,045	N/A
12/31/2021	157,609	23,267	N/A	N/A	N/A
9/30/2021	157,389	23,269	17,283	28,059	N/A
6/30/2021	156,130	22,600	N/A	N/A	N/A
3/31/2021	144,035	22,016	24,399	32,939	N/A
12/31/2020	150,076	18,465	N/A	N/A	N/A
9/30/2020	148,501	16,932	18,757	27,798	N/A
6/30/2020	143,967	13,270	N/A	N/A	N/A
3/31/2020	142,531	11,766	20,274	29,315	N/A
12/31/2019	142,338	12,448	N/A	N/A	N/A
9/30/2019	141,736	13,816	26,553	34,629	N/A
6/30/2019	137,682	16,919	N/A	N/A	N/A
3/31/2019	131,656	18,488	2,245	12,819	N/A
12/31/2018	126,706	19,954	N/A	N/A	N/A
9/30/2018	123,526	20,305	N/A	N/A	N/A
6/30/2018	126,133	21,168	N/A	N/A	N/A
3/31/2018	119,049	17,946	-1,300	9,193	N/A
12/31/2017	111,691	15,705	N/A	N/A	N/A
9/30/2017	102,206	13,511	N/A	N/A	N/A
6/30/2017	93,397	12,277	N/A	N/A	N/A
3/31/2017	93,765	14,904	N/A	13,117	N/A
12/31/2016	97,494	11,323	N/A	N/A	N/A
9/30/2016	97,971	12,812	N/A	N/A	N/A
6/30/2016	97,221	14,186	N/A	N/A	N/A
3/31/2016	94,268	19,339	N/A	18,935	N/A
12/31/2015	95,901	14,843	N/A	N/A	N/A
9/30/2015	92,453	13,766	N/A	N/A	N/A
6/30/2015	89,795	12,638	N/A	N/A	N/A
3/31/2015	86,513	11,506	N/A	9,936	N/A
12/31/2014	82,955	10,394	N/A	N/A	N/A
9/30/2014	79,777	9,435	N/A	N/A	N/A
6/30/2014	76,165	8,488	N/A	N/A	N/A
3/31/2014	72,034	8,036	N/A	9,028	N/A
12/31/2013	68,204	8,266	N/A	N/A	N/A
9/30/2013	65,528	7,430	N/A	N/A	N/A
6/30/2013	64,007	6,561	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (8.3% al año) de ZYDUSLIFE es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (8.3% al año) de ZYDUSLIFE crezcan menos que el mercado Indian (17.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de ZYDUSLIFE crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (7.4% al año) de ZYDUSLIFE crezcan más despacio que el mercado de Indian (10.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 7.4% al año) de ZYDUSLIFE crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ZYDUSLIFE sea baja dentro de 3 años (13.5%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Zydus Lifesciences Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Price target increased by 7.6% to ₹536

Recent updates

Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S

Insider recently sold ₹833k worth of stock

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg

Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1

Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma.

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Upcoming dividend of ₹6.00 per share at 1.0% yield

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Zydus Lifesciences Limited Receives Final Approval from the Usfda for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 Mg and 40 Mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Price target increased by 7.6% to ₹536

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Zydus Group Reportedly Looks to Sell Cliantha Research

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Sirolimus Tablets, 1 Mg and 2 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Febuxostat Tablets

Zydus Lifesciences Limited Receives Two Final Approvals from the USFDA for Silodosin Capsules and Pregabalin Capsules

Zydus Lifesciences Limited Receives Final Approval from United States Food and Drug Administration to Market Topiramate Extended-Release Capsules

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) entered into a Business Transfer Agreement to acquire Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma for approximately INR 470 million.

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Famotidine Injection

Zydus Lifesciences Limited Gets Exclusive Marketing Rights for CanAssist Breast

Insufficient new directors

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide Tablets

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Acetaminophen Injection

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Micafungin for Injection

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Ketorolac Tromethamine Tablets

Investor sentiment improved over the past week

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Lenalidomide Capsules 5 Mg, 10 Mg, 15 Mg and 25 Mg

Zydus Lifesciences Limited Receives Final Approval and 180 Days Shared Exclusivity from the USFDA for Cariprazine Capsules

Zydus Lifesciences Ltd. Achieves Positive Proof-of-Concept in its Phase 2 Clinical Study of ZYIL1, in Patients with CAPS

Zydus Lifesciences Ltd. Announces Phase IV DREAM-CKD Trial to Generate Real World Evidence of Desidustat in Patients with Chronic Kidney Disease Induced Anemia

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Shares Could Be 23% Below Their Intrinsic Value Estimate

Zydus Receives Final Approval from the USFDA for Ivermectin Cream

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Bisoprolol Fumarate Tablets

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year